ABSTRACT TGFBR3 (betaglycan), a TGFbeta superfamily coreceptor, is essential for normal seminiferous cord and Leydig cell development in the fetal mouse testis and has been associated with testicular dysgenesis syndrome in men. However, the mechanisms underlying TGFBR3-regulated testis development are unclear. We tested the hypothesis that loss of Tgfbr3 compromises the functions of TGFbeta2 in the differentiating fetal testis. Analysis of expression of transcripts encoding the TGFbeta superfamily members showed a predominance of TGFbeta mRNAs during the critical window of development when testis structure is established (11.5-14.5 days postcoitum [dpc]). When cultured under basal conditions for 2 days, explants of 13.5 dpc wild-type fetal testis/mesonephros complexes exhibited structure and gene expression profiles resembling those observed in vivo between 13.5-15.5 dpc. Similarly, development of Tgfbr3 knockout testis explants recapitulated the dysgenesis and decreased somatic cell marker expression previously observed in vivo. TGFbeta2 treatment partially rescued cord development in 11.5-13.5 dpc Tgfbr3 knockout explants but did not significantly alter somatic or germ cell gene expression. In contrast, TGFbeta2 treatment of wild-type explants disrupted cord structure and significantly downregulated the somatic and steroidogenic cell markers Amh, Sf1, Star, Cyp11a, Hsd3b1, and Cyp17a1. We conclude that 1) the compromised cord development in Tgfbr3 null fetal testis is due to, at least in part, disrupted TGFbeta2 function; 2) the reduction in steroidogenesis observed in the Tgfbr3 null testis may be regulated by additional TGFBR3 ligands, rather than TGFbeta2; and 3) both cord maintenance and somatic cell development are highly sensitive to the levels of TGFbeta2.
INTRODUCTION
Testicular dysgenesis syndrome (TDS) consists of a group of disorders, which include hypospadia, cryptorchidism, testicular cancer, and low sperm counts [1, 2] . TDS is thought to be caused by defects in early testis development, and both environmental and genetic factors have been implicated in the etiology of TDS [1, 2] . However, very little is known about the specific genes or mechanisms involved. Studies in rat suggest that defects in early testis development that disrupt normal androgen production result in problems in the masculinization of the fetus, which may manifest as TDS in adulthood [3] . In particular, recent evidence indicates that disrupted fetal Leydig cell function during a defined period of early fetal testis development (the masculinization programming window) is correlated to the degree of testicular dysgenesis following fetal di-n-butyl phthalate exposure [4] . Genetic causes of TDS are less well understood, although recent evidence from a genomewide association analysis indicates that genetic variants of TGFBR3 are correlated with the occurrence of TDS symptoms in men [5] . This suggests that a subset of TDS cases may have a common genetic predisposition, associated with disrupted TGFBR3 function [5] .
TGFBR3 encodes betaglycan, formally known as the type III transforming growth factor-beta (TGFb) receptor, a coreceptor for the TGFb superfamily that confers the highpotency actions of its ligands [6, 7] . The TGFb superfamily includes a large group of multifunctional growth factors that play multiples roles in organogenesis, regulating cellular proliferation, survival, differentiation, and extracellular matrix production [8] . Members of the TGFb superfamily play key roles in establishing fetal testis structure as indicated by defects in testis structure in several TGFb superfamily knockout mouse models [9] [10] [11] . TGFb isoform signaling is mediated by two serine-threonine kinase receptors, the type I and II TGFb receptors (TGFBR1 and TGFBR2). In addition, TGFBR3 has been shown to bind TGFb isoforms 1, 2, and 3 as well as inhibins with high affinity, modulating the association of these ligands with type II receptors [12] .
In accordance with the hypothesis that TGFBR3 plays a role in fetal testis development and ultimately TDS, we have previously shown that Tgfbr3 is expressed within the somatic cell compartments of the mouse fetal testis [13] and Tgfbr3 knockout mouse embryos exhibit defects in fetal testis cord structure and Leydig cell differentiation at midgestation [14] . In this current study, we sought to better define the roles of Tgfbr3 in fetal testis in order to gain insights into its mechanisms of action in normal and dysgenic testicular development. Firstly, we characterized the expression levels of the genes encoding TGFBR3's ligands during the early period of gonad development (11.5-14.5 days postcoitum [dpc]), when testis development is most susceptible to perturbation [4] . We then used a fetal testis explant culture system to examine the effects of Tgfbr3 loss on TGFbmediated events during testis development. In particular, TGFBR3 is essential in many cellular contexts to increase sensitivity to TGFb2, which binds poorly to the type I and II receptors in the absence of TGFBR3 [15] . Therefore, we tested the specific hypothesis that loss of Tgfbr3 compromises the functions of TGFb2 in the differentiating fetal testis.
MATERIALS AND METHODS

Animals, Genotyping, and Sexing of Embryos
Pregnant dams were obtained from timed matings of Tgfbr3 heterozygote female and male mice (C57BL6 X sv129 background) [15] . Noon on the day of vaginal plugging was designated as 0.5 dpc, and the sex and genotype of the embryos were determined as previously described [14] . All the animal handling and experimental procedures were approved by the Monash Medical Centre Animal Ethics Committee.
Explant Culture
Testes/mesonephroi complexes (n ¼ 3-5/genotype/TGFb2 dose) were dissected out of 11.5 and 13.5 dpc embryos and placed in grooves on 2% agar blocks, according to a previously published method [16] . Gonads were cultured at 378C and 5% CO 2 for 48-72 h, as indicated, in Dulbecco modified Eagle medium plus 10% heat-inactivated fetal calf serum and 5 lg/ml transferrin (Sigma-Aldrich), 2.5 mM L-glutamine (Trace Bioscience), 100 lg/ml penicillin, and 100 lg/ml streptomycin. Testes explants were cultured with or without recombinant human TGFb2 (R & D Systems) at the doses stated in the text. For each sample, 300 ll of media was added to a gel slab in each well of a 12-well plate. At the completion of the culture period, gonad/mesonephros complexes were separated according to genotype and either snap frozen for RNA extraction or fixed in Bouin solution for histological analysis. For gene expression analysis, at least five different individual testis explants were examined from Tgfbr3 knockout and wild-type embryos. For estimates of gonad size, whole cultured testes were imaged on the first day of culture and at culture endpoint. Total gonad area measurements were obtained by tracing the circumference of each testis explant (n ¼ 3-5/genotype) in images of the cultures using Professional AnalySIS imaging software (Olympus).
Processing of Gonads and Explants for Real-Time PCR Analyses
For gene expression analyses, independently collected sets of Tgfbr3 knockout, heterozygous, and wild-type testis at 11.5, 12.5, 13.5, and 14.5 dpc were used. Gonads were dissected free from the mesonephroi and separated according to genotype. At least three different pools from each age were examined, each comprising three to four pairs of gonads. For explant cultures, single testis-mesonephros explants were used (one explant per embryo was TGFb2-treated; the contralateral served as an untreated control). Five explants/ genotype/treatment were assayed in parallel. Total mRNA was extracted from each tissue sample, and the contaminating DNA was removed using the RNeasy Micro or Mini Kit (Qiagen) as recommended by the manufacturer's protocol. Extracted RNA was quantified using the ND-1000 Nanodrop spectrophotometer (NanoDrop Technologies Inc.). Complementary DNA was synthesized from 250 ng of RNA using Expand Reverse Transcriptase (Roche), random hexamer, and oligo d(T)20 primers as previously described [17] .
Primer Design and Preparation of Standards for Real-Time PCR Analysis
The primers used for quantitative real-time PCR (qRT-PCR) were either previously published [14] or designed for this study, as listed in Table 1 . Each primer set was created to span an intron to exclude genomic DNA contamination. A PCR product was amplified for each set of primers, purified using the QIAquick Gel Extraction kit (Qiagen), quantified using the ND-1000 Nanodrop spectrophotometer, and verified by sequencing. The PCR product was then used as the positive internal control and was diluted from 500 fg to 0.05 fg for use as a standard for quantitative analysis. The analysis was performed as described previously [14, 18] .
Quantitative Real-Time PCR
Quantitative RT-PCR analysis was performed to determine changes in the expression levels of the genes encoding key TGFb ligands and specific cell lineage markers, as previously reported [14] . All the gene expression assays were performed in parallel for each sample. PCR samples were prepared to a final volume of 10 ll using the Applied Biosystems ABI SYBR mix (Scoresby). Quantitative RT-PCR was performed using the Applied Biosystems ABI 7900 HT Fast real-time machine. Cycling conditions consisted of a 10 min initial denaturation step at 958C, then 55 cycles of denaturing (958C for 15 sec), annealing (558C or 618C for 5 sec), and elongation (728C for 8 sec, followed by 798C for 10 sec). Data collection was captured at 958C for 15 sec and 798C for 10 sec to eliminate primer dimers from the analysis. All the qRT-PCR reactions were performed in triplicate. For negative controls, water was used in place of the reverse-transcribed template for each primer pair. The results were confirmed in two independent experiments.
Histological Staining and Immunohistochemistry
For histology, cultured gonads were fixed with Bouin solution for 2 h and then washed with 70% ethanol. After fixation, the samples were dehydrated and embedded in paraffin. Serial sections (4 lm) through entire organs were collected onto Superfrost slides. For histological evaluation, every tenth section was stained with hematoxylin-eosin. Immunohistochemistry was performed as previously described [14] . Antigen retrieval was performed in 50 mM glycine pH 3.5, maintained at 908C for 10 min. A monoclonal primary antibody against INHA (inhibin alpha, 1:800; gift of Professor David Robertson, Prince Henry's Institute, Australia) or polyclonal primary antibodies against TGFb2 (sc-90, 1:50; Santa Cruz), CYP11A1 (also known as P450-cholesterol side chain cleavage) (ab1294, 1:800; Abcam), AMH (also known as MIS) (sc-6886, 1:400; Santa Cruz), SOX9 (sc-20095, 1:100; Santa Cruz), or DDX4 (also known as MVH) (ab13840, 1:800; Abcam), or laminin polyclonal antibody (L9393, 1:1000; Sigma) were applied for overnight incubation in 0.1% bovine serum albumin/phosphate buffered solution (PBS). Subsequent steps were performed at room temperature with PBS washes between incubations. Biotinylated sheep anti-mouse inhibin alpha, goat anti-rabbit CYP11A1, SOX9, DDX4, and laminin, and rabbit anti-goat secondary antibodies (AMH) were used at 1:500 for 1 h and then the Vectastain Elite ABC kit was used, according to the manufacturer's instructions (Vector Laboratories). Antibody binding was detected as a brown precipitate following development with 3,3 0 -diaminobenzidine tetrahydrochloride, and Harris hematoxylin was used as counterstain. The sections were mounted under glass coverslips in Depex (BDH Laboratory Supplies). Appropriate isotype (immunoglobulin G [IgG]) negative controls were performed on matched sections in every experiment.
Apoptosis and Proliferation Assays
For assessing apoptosis, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) was performed using the ApopTag Peroxidase In Situ Apoptosis Detection kit per the manufacturer's instructions (S7100; Chemicon). As a negative control, sections were incubated with the label solution only, which lacked terminal transferase. Morphometric analysis was performed on images as described previously [14] . Brown-stained TUNEL-positive cell numbers were quantified per testis section using Professional AnalySIS software (Olympus). TUNEL-positive cell number per square micrometer was calculated as percentage per total area (in lm 2 ). To detect proliferating cells, PCNA immunostaining was performed using a monoclonal antibody to PCNA (1:800; Dako), as in the above described immunohistochemistry method. To detect the primary antigen, a biotinylated sheep anti-mouse secondary antibody was used at 1:500. Mouse IgG was used in place of the PCNA antibody for the negative controls.
Flow Cytometry
Flow cytometry was performed as previously described with the following variations [19] . Cultured testes were grown with 20 lM 5-ethynyl-2 0 -deoxyuridine (EdU) for 2.5 h before collection for analysis. Embryonic gonad/mesonephros explants were dissociated using trypsin/ethylenediaminetetraacetic acid and incorporated EdU was detected using the 647-Click-iT Flow Cytometry kit (Invitrogen) with modifications to the protocol as described below. Germ cells were identified by their positive immunoreactivity with a MVH primary antibody (1:300; Abcam) detected using a goat-anti rabbit AlexaFluor 488 secondary antibody (1:500; Invitrogen). All the washes were performed in 50 ll of the Alexa 647 Click-iT EdU Flow Cytometry kit permwash solution. DNA was stained with 10 lg/ml propidium iodide. Samples containing a minimum of 10 000 germ cells were analyzed using an LSRII flow cytometer (BD Biosciences) utilizing FACSDiVa software (BD Biosciences). The cell cycle state was assessed on DNA content using ModfitLT (Verity Software House) software. Three to five biological replicates were analyzed for each genotype.
Statistical Analysis
Statistical analyses were conducted using GraphPad Prism (version 5). The means of the qRT-PCR data were compared using ANOVA followed by a post SARRAJ ET AL.
hoc Tukey multiple comparisons test. FACS data (flow cytometry) were analyzed with a Kruskal-Wallis test followed by a Dunn multiple comparisons test. Means of testis area measurements were compared using two-tailed t-tests. A P value of 0.05 or less was considered significant.
RESULTS
Differential Expression of TGFb Superfamily Genes in the Developing Mouse Testis
The male mouse gonad undergoes rapid structural changes in utero after 11.5 dpc, leading to the formation of the testis cords and male-specific vasculature by 12.5 dpc [20] . By 13.5 dpc, the fetal Leydig cells begin to differentiate within the testis interstitium and actively express steroidogenic enzymes and other factors required for normal male reproductive tract development [21, 22] . To verify the presence of TGFb ligands at these critical early stages of fetal testis development (11.5-14.5 dpc), the expression levels of TGFb superfamily genes were examined in wild-type and Tgfbr3 knockout testis by qRT-PCR. In the wild-type Sry-expressing bipotential gonad at 11.5 dpc, the expression levels of the genes encoding the inhibin-alpha (Inha), activin beta A (bA subunit, Inhba), and activin beta B (bB subunit, Inhbb) were just above the level of detection and significantly increased thereafter until 14.5 dpc (P , 0.05; Fig. 1 , A-C). Inha, Inhba, and Inhbb mRNAs were expressed at similar levels across the genotypes from 11.5 to 13.5 dpc but were significantly decreased in Tgfbr3 knockout testis compared to wild type at 14.5 dpc (65%-80%, P , 0.05; Fig. 1 , A-C). In contrast, Tgfb1, Tgfb2, and Tgfb3 gene expression was readily detected in the wild-type bipotential gonad, after which Tgfb2 was downregulated while the expression levels of Tgfb1 and Tgfb3 did not change significantly with age ( Fig. 1, D-F ). In the absence of Tgfbr3, the expression of Tgfb1b and Tgfb2 at 12.5 dpc was decreased (21% and 39%, respectively, P , 0.05) compared to wild-type levels ( Fig. 1 , D and E), but no differences in the expression levels of Tgfb1, Tgfb2, or Tgfb3 amongst the genotypes were detected at the other ages ( Fig. 1, D 
and E).
Morphological Effects of In Vitro Addition of TGFb2 to Wild-Type and Tgfbr3 Knockout Testis Explants
Establishment of explant culture model. To investigate the function of Tgfbr3 relative to TGFb2, wild-type and Tgfbr3 knockout testis-mesonephros explants from 11.5 and 13.5 dpc embryos were cultured in vitro. The age of the explants and culture periods were chosen to encompass the window of development from 11.5-15.5 dpc when the testis structure is first established in mouse and the Tgfbr3 null testis phenotype was most pronounced [14] . The majority of the experiments were conducted on the 13.5 dpc explants cultured for 2 days to examine how genotype and treatment affected cord structure and maintenance. Cord morphology was also assessed in 11.5 dpc explants cultured for 3 days to determine whether similar effects were observed during the earlier time period when testis cords were first established. In both 11.5 dpc (Supplemental Fig. S1 , all the Supplemental Data are available online at www. biolreprod.org) and 13.5 dpc explant cultures (Fig. 2, A and F) , development of the wild-type testis recapitulated normal cord development in vivo. Similarly, the development of cultured Tgfbr3 knockout testis resembled the in vivo Tgfbr3 knockout mouse testis phenotype during the corresponding stage of 
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development, that is, explanted knockout testis showed disrupted cord formation, with cord borders poorly delineated from the surrounding interstitium, which was noticeable both in the 11.5 dpc explants cultured for 3 days (Supplemental Fig.  S1 ) and in the 13.5 dpc explants cultured for 2 days (Fig. 2, B and G). To test our hypothesis that the absence of TGFBR3 compromised TGFb2-mediated events in developing testis, the effects of exogenous TGFb2 on wild-type and Tgfbr3 null explants were studied. Separate explants were made from individual embryos such that one testis-mesonephros complex was treated with TGFb2 and the contralateral complex served as an untreated control. An initial titration experiment was performed using 13.5 dpc explants and 1.25, 2.5, and 5 ng/ml concentrations of TGFb2; 1.25 ng/ml TGFb2 did not affect explant morphology at any time point (data not shown) while 2.5 ng/ml and 5 ng/ml (data not shown) for 48 h produced similar morphological effects on the testicular cords. Consequently, 2.5 ng/ml TGFb2 was used in all the experiments.
Effect of exogenous TGFb2 on testis size and cellular turnover. Morphometric analysis of testis size, based on the gonad surface area in whole longitudinal gonad images (Fig.  2E) , revealed that TGFb2 treatment resulted in a 35% reduction in the size of wild-type 13.5 dpc mouse testis explants when compared to untreated controls (Fig. 2, A, C, and E) . In contrast, the size of untreated Tgfbr3 knockout testis explants FIG. 1. Tgfbr3 knockout testis exhibits differential expression of TGFb superfamily genes between 11.5-14.5 dpc. A-F) The expression levels of the genes encoding Inha (A), Inhba (B), Inhbb (C), Tgfb1 (D), Tgfb2 (E), and Tgfb3 (F) in 11.5, 12.5, 13.5, and 14.5 dpc wild-type and Tgfbr3 knockout testis were determined by qRT-PCR and normalized to 18S rRNA levels. Means 6 SD of triplicate measurements in a representative assay is shown. Three independently collected pools of testes were examined in each assay (n ¼ 3-4 testes/pool). *P , 0.05 and ***P , 0.001 represent significant changes within the genotypes over days of development (a, b: P , 0.05; c, d: P , 0.001).
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did not significantly differ from wild-type controls (Fig. 2, A,  B , and E), and nor did the addition of TGFb2 to knockout 13.5 dpc explants alter testis size (Fig. 2, B, D, and E) . In addition, neither TGFb2 treatment nor genotype affected the size of 11.5 dpc explants after 3 days culture (data not shown). To determine the underlying causes of the reduction in 13.5 dpc explant size following TGFb2 treatment, we used TUNEL to assess apoptosis. In both 13.5 dpc wild-type and Tgfbr3 null explants, apoptotic cells were detected in the interstitium of both wild-type and knockout testis explants after 48 h of culture (Fig. 2, F and G) . Treatment with TGFb2 increased the level of apoptosis within the interstitium 2.3-fold (P , 0.0001) 
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in the wild-type explants but not in the knockout explants (n ¼ 3; Fig. 2, H-J) . PCNA immunostaining, which detects proliferating cells, was abundant in all the explants, with no change after treatment with TGFb2 in either genotype tested (data not shown). These results were verified using FACS analysis and DDX4 immunostaining to quantity subpopulations of germ (DDX4-positive) and somatic (DDX4-negative) cells. This analysis was performed in conjunction with EdU incorporation, which enabled the quantification of the proliferating cells in each subpopulation. This analysis indicated no statistical differences in the proportion of germ cells and somatic cells with genotype or treatment ( Table 2) . Furthermore, the proportion of cells in each subpopulation that were proliferating did not differ with genotype or treatment ( Table  2) .
Effect of exogenous TGFb2 on testis cord structure and maintenance. In 13.5 dpc explants cultured for 2 days, testis morphology was visualized by laminin immunostaining, which localizes to the interstitium and basal lamina of the cords, enabling assessment of testis cord structure (Fig. 3, A-D) . In untreated control cultures, testis cords were well-organized and clearly delineated by a boundary of peritubular cells (Fig. 3, A and A 0 ). TGFb2 treatment caused cord disruption in the wildtype testis, with a loss of cord-interstitial boundaries within localized areas of dysgenesis (Fig. 3 , C and C 0 ). In the untreated knockout testis, the germ and somatic cells were aberrantly aggregated and there was no clear delineation of the seminiferous cords (Fig. 3, B and B 0 ). TGFb2 treatment of knockout explants resulted in a partial recovery of the testis structure, as assessed by the appearance of distinct boundaries between the cords and interstitium (Fig. 3, D and D  0 ). This effect was most pronounced near the medial edge of the testis, where germ and Sertoli cells encapsulated by peritubular myoid cells could now be observed (Fig. 3, D and D 0 ).
TGFb2-Mediated Regulation of Genes Encoding TGFb Ligands and Germ Cell and Somatic Cell Markers in WildType and Tgfbr3 Knockout Mouse Testis Explants
Effect of exogenous TGFb2 on testis gene expression: TGFBR3 ligands. We used qRT-PCR to determine the effects of explant culture and exogenous TGFb2 treatment on the endogenous expression patterns of the TGFBR3 ligands in the wild-type and knockout fetal testis explants. Following culture for 2 days under basal conditions, the mRNAs encoding TGFb1, TGFb2, and TGFb3 and the activin and inhibin subunits were readily detectable in both wild-type and Tgfbr3 knockout explants (Fig. 4) . The Tgfbr3 knockout testis explants displayed significant reductions in endogenous Tgfb1, Tgfb2, and Inhba expression levels (approximately 50%, P , 0.05) when compared to wild-type explants (Fig. 4, B, D , and E). When cultured in the presence of exogenous TGFb2, the mRNA levels of Tgfb1, Tgfb2, Tgfb3 (Fig. 4, D-F) , and Inhbb (Fig. 4C) were maintained in the wild-type explants while expression of Inhba (32%, P , 0.001; Fig. 4B ) and Inha (45%, P , 0.05; Fig. 4A ) were significantly decreased. In contrast, TGFb2 treatment had no significant effect on the expression of TGFb superfamily member genes in Tgfbr3 knockout explants (Fig. 4, A-F) . Similar to the qRT-PCR results, immunostaining demonstrated that TGFb2 treatment decreased INHA protein levels in the wild-type testis while expression was retained in the Leydig cells of the knockout testis (Fig. 4, G-J) .
Effect of exogenous TGFb2 on testis gene expression: somatic cell markers. We have shown previously that the absence of Tgfbr3 in vivo during early fetal testis development results in a significant reduction in the expression levels of a number of genes important for steroid hormone synthesis, indicating a disruption to fetal Leydig cell development and/or function [14] . Therefore, we examined using qRT-PCR whether exogenous TGFb2 restored steroidogenic gene expression associated with Leydig cells in the Tgfbr3 knockout testis. Cultured wild-type mouse testes exhibited a significant 43% (P , 0.0001) decrease in the expression of the somatic marker Nr5a1 (previously known as steroidogenic factor-1, or Sf1) after treatment with TGFb2 (Fig. 5A) . Furthermore, Star (52.5%), Cyp11a1 (86.8%), Hsd3b1 (65%), and Cyp17a1 (74.4%) were also significantly decreased in response to TGFb2 in wild-type explants (Fig. 5, B-E) while Insl3, the gene encoding for INSL3, a hormone produced by the Leydig cells, was not affected (Fig. 5F ). As expected from our original study [14] , the expression levels of these genes in the Tgfbr3 knockout testis explants were significantly reduced compared to wild-type testis (Fig. 5, A-F) . Furthermore, TGFb2-treatment of Tgfbr3 null testis explants for 2 days did not change the expression levels of the Leydig cell markers when compared to Tgfbr3 null control testis (Fig. 5, A-F) . Immunohistochemistry using an antibody to detect CYP11A1 in cultured explants recapitulated the qRT-PCR results (Fig. 5 , G-J). In accordance with our original results using freshly isolated 12.5-14.5 dpc testis [14] , CYP11A1 was readily detected in developing Leydig cells in wild-type testis explants but was greatly reduced in Tgfbr3 null explants (Fig. 5, G and  H) . Similarly with the qRT-PCR analyses of the current study, CYP11A1 protein levels were greatly reduced in wild-type explants following TGFb2 treatment but unchanged in knockout explants (Fig. 5, I and J ).
An assessment of Sertoli cell markers revealed differential regulation by TGFb2. In the Tgfbr3 knockout explants, Sox9, but not Amh (anti-Müllerian hormone, also termed Müllerian inhibitory substance), expression was significantly reduced by 36% (P , 0.05) compared to wild type. While Sox9 expression was unaffected by TGFb2 treatment in the wild-type explants, Amh expression in contrast was significantly downregulated at the mRNA level (58%, P , 0.001; Fig. 6, A and B) and the protein level (Fig. 6, C and E) . Following culture in the presence of TGFb2, the levels of Sox9 and Amh mRNA SARRAJ ET AL. 
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expression were not significantly altered in Tgfbr3 knockout explants (Fig. 6, A and B) . However, AMH protein staining appeared increased in the treated knockout testis explants when compared to the untreated cultures (Fig. 6, D and F) .
Effect of exogenous TGFb2 on testis gene expression: germ cell markers. Our analysis of DDX4-positive cells by FACS did not reveal any significant differences with TGFb2 treatment or genotype (Table 2) , indicating sustained germ cell numbers in our explant cultures. To determine whether treatment or genotype affected gene expression within germ cells, we examined the levels of expression of two mouse germ cell genes by qRT-PCR, the early pluripotent germ cell marker Pou5f1 (previously known as Oct4) and the germ cell marker Ddx4 (mouse Vasa homologue or Mvh). The mRNAs of both genes were detectable in all the explants after 48 h of culture (Fig. 7) . Neither genotype nor treatment with TGFb2   FIG. 6 . Assessment of Sertoli cell markers in fetal testis explants in response to TGFb2 treatment. A, B) Genes encoding for the Sertoli cell markers Sox9 (A) and Amh (B) were analyzed using qRT-PCR in wild-type and Tgfbr3 knockout gonad cultured with or without TGFb2 and normalized to 18S rRNA. Means 6 SD of triplicate measurements of expression within single explants (n ¼ 5 explants/genotype/treatment) are shown *P , 0.05, ***P , 0.001. C-F) Immunostaining for AMH (brown product) in sections through wild-type and Tgfbr3 knockout testis explants cultured for 48 h in the presence and absence of TGFb2. Black arrow indicates Sertoli cell. Dotted lines denote the boundary of representative cords (Co). Bar ¼ 50 lm.
significantly changed the expression of Pou5f1 (Fig. 7A) . In contrast, Ddx4 mRNA expression was significantly reduced in the Tgfbr3 knockout testis (28%, P , 0.01) when compared to untreated wild-type explants (Fig. 7B) . Ddx4 mRNA expression was also reduced in wild-type explants by TGFb2 treatment (27%, P , 0.01) but did not change in Tgfbr3 knockout testis following TGFb2 treatment (Fig. 7B) .
DISCUSSION
Recent evidence from a human genomewide association study identified genetic variants of TGFBR3 that showed an association with human TDS phenotypes, particularly testicular germ cell cancer and cryptorchidism [5] . We have previously established that Tgfbr3 is essential for normal testis cord development and differentiated fetal Leydig cell function by using a knockout mouse model [14] . Collectively, these studies suggested that TGFBR3-regulated pathways and developmental processes in fetal testis are essential for normal adult testis structure and function. In the current work, we employed in vitro gonad culture to further investigate the mechanisms by which Tgfbr3 contributes to testis development, demonstrating that exogenous TGFb2 partially rescues the dysgenic cord phenotype but not the deficits in Leydig cell gene expression in fetal Tgfbr3 knockout testis (summarized in Supplemental Table S1 ). These data indicate that the structural defects in Tgfbr3 null testis are due at least in part to compromised TGFb2 function but that the Leydig cell defects may involve additional TGFBR3 ligands.
Growing Evidence Indicates an Essential Role for TGFb2/ TGFBR3 Signaling During Early Testis Cord Development and Cord Maintenance TGFBR3 is capable of binding multiple TGFb superfamily members, although in many physiological contexts, TGFBR3 appears most important for high-potency TGFb2 [15] and inhibin action [23] . The current study demonstrates that, of the TGFBR3 ligands, the TGFbs and inhibins are more prevalently expressed in the 11.5-12.5 dpc testis as it first differentiates from the bipotential gonad. These data suggest that one or more of the TGFbs may act via TGFBR3 during the early stages of fetal testis development when cord structure is first being established. In addition, the morphology data derived from the 13.5 dpc explants that were cultured in the presence and absence of TGFb2 indicate that TGFbs also regulate testis development after cords have already formed. This conclusion is in broad agreement with the existing literature on knockout mouse models of the TGFb ligands, which suggest regulatory roles for the TGFbs at multiple stages of testis formation [10] . In particular, Tgfb2 knockout mice exhibit decreased fetal testis cord integrity at 15 dpc [10] . In addition, TGFb2 has been shown to be a paracrine modulator of Sertoli-peritubular myoid cell interactions in the rat testis, inducing clustering and aggregation of Sertoli cells in vitro [24, 25] . These data, coupled with our current demonstration that TGFb2 partially rescues cord structure in Tgfbr3 null testis, suggest that TGFb2 is the endogenous ligand for TGFBR3 that predominantly regulates early cord formation and/or maintenance. However, the fact that restoration of cord structure by TGFb2 was partial and that in addition to Tgfb2 we detected transcripts for Tgfb1 and Tgfb3 during early testis formation suggests a contribution from the other TGFBR3 ligands at this time of development.
TGFb2/TGFBR3-Mediated Apoptosis May Contribute to the Establishment of Fetal Testis Size
In the current study, we demonstrate that TGFb2 treatment of wild-type 13.5 dpc testis explants results in a significant decrease in explant size, a corresponding increase in cellular apoptosis, particularly in the interstitial compartment, and no change in germ or somatic cell proliferation. This indicates that TGFb2 may normally contribute to the controlled growth of the testis during the window of 13.5-15.5 dpc, which corresponds to the culture period, and does so at least in part by stimulating somatic cell apoptosis. Furthermore, TGFb2 appears to require TGFBR3 to induce apoptosis within explanted fetal testis because testis size was not significantly affected and no increase in apoptosis was observed following TGFb2 treatment of Tgfbr3 knockout testis explants. This is in keeping with our previous work indicating that Tgfbr3 is an important determinant of TGFb2 efficacy in many cell types, enabling critical signaling thresholds to be met during heart and kidney development that enable proper morphogenesis of these organs [15] . The expression of genes encoding Pou5f1 (also known as Oct4; A) and Ddx4 (also known as Mvh; B) were determined in wild-type and Tgfbr3 knockout gonad explants with or without TGFb2 treatment using qRT-PCR and normalized to 18S rRNA levels. Means 6 SD of triplicate measurements of expression within single explants (n ¼ 5 explants/genotype/treatment) are shown; **P , 0.01, ***P , 0.001.
TGFBETA2 EFFECTS ON FETAL TESTIS
TGFb2 treatment also partially rescued the disorganized cord phenotype exhibited by the Tgfbr3 knockout testis explants. This indicates that TGFb2 can stimulate the establishment and/or maintenance of cord structure in fetal testis explants and that the dose of exogenous TGFb2 used in this study, together with endogenously produced TGFb2, was sufficient to influence cord formation in the absence of Tgfbr3. This is not entirely unexpected as a previous study has demonstrated that at high doses TGFb2 can bind directly to its receptor, TGFBR2, at sufficient levels to meet signaling thresholds, thereby bypassing the need for TGFBR3 [15] . The fact that TGFb2 treatment also caused dysgenesis in the wild-type explant cultures suggests the need for carefully balanced levels of TGFb2 action for normal cord development to occur. In accordance with this interpretation, autocrine TGFb2 has previously been shown to induce growth arrest and differentiation in podocyte culture while increased TGFb2 concentration, by the addition of exogenous TGFb2, resulted in the activation of alternate cell signal pathways and cellular apoptosis [26] .
TGFb2/TGFBR3 Regulation of Fetal Testis Somatic Cell Gene Expression
As we observed in freshly dissected testis tissues [14] , the absence of Tgfbr3 resulted in greatly reduced levels of somatic cell markers in the explant cultures. Unlike in wild-type cultures, exogenous TGFb2 did not alter the expression of Sertoli and Leydig cell markers in Tgfbr3 knockout testis explants. This is consistent with an essential role for TGFBR3 in facilitating ligand-dependent stimulation of Sertoli and Leydig cell function. Quantitative assessment of the effects of TGFb2 treatment on Leydig cell markers in wild-type fetal mouse testis explants allowed us to distinguish between the roles of TGFb2 in the regulation of fetal Leydig cell capacity for steroidogenesis. Notably, cultured wild-type mouse testes exhibited a significant decrease in the expression of Leydig cell steroidogenic markers after treatment with TGFb2 while the expression of Insl3, the gene encoding for Leydig cell INSL3 hormone, was not affected. These data suggest that steroidogenesis, rather than Leydig cell differentiation or Leydig cell number, was negatively regulated by exogenous TGFb2 treatment. These results are in agreement with the current FACS data that indicate no change in somatic cell proliferation following TGFb2 treatment as well as a previous study using dispersed fetal rat testis where TGFb1 was found to negatively regulate fetal testis steroidogenesis in vitro [27] . TGFbs may act to limit androgen production in fetal mouse testis, which would affect androgensensitive developmental processes such as male reproductive tract specification and formation and lead ultimately to TDS.
TGFb2 treatment of wild-type testes also differentially affected Sertoli cell markers, downregulating Amh but not Sox9, suggesting that Tgfb2 may function upstream of Amh in the fetal testis and does not require TGFBR3 for this regulation. However, AMH protein levels appeared to be retained, or even increased, within the cords in wild-type and Tgfbr3 explants treated with TGFb2. These data indicate a differential regulation of Amh mRNA and protein in fetal testis explants. In particular, AMH levels appeared to be correlated to the relative degree of cord maintenance in TGFb2-treated cultures. This may indicate that AMH protein is regulated by additional factors in the treated cultures, such as a TGFb2-induced increase in Sertoli cell-cell interactions, a TGFb2 function suggested in previous studies [24, 25] . More detailed study is required to understand the significance of these observations.
Distinct TGFb/TGFBR3-Mediated Effects on Fetal Germ Cell Gene Expression
We found that expression of the differentiated germ cell marker Ddx4 was downregulated in knockout testis explants and in both knockout and wild-type testis explants following TGFb2 treatment while that of the early pluripotency marker Pou5f1 was not affected by either genotype or treatment. The differential regulation of Ddx4 and Pou5f1 suggests that germ cell differentiation, rather than primordial germ cell survival or proliferation during early testis development, is specifically affected by TGFb2 treatment and Tgfbr3 loss. However, our FACS analyses indicate that the number of DDX4-positive cells did not differ with TGFb2 treatment or with genotype, which suggests that TGFb2/TGFBR3 regulate germ cell gene expression rather than male germ cell number in fetal murine testis. This is in keeping with our previous findings where DDX4 protein expression was not altered in the Tgfbr3 knockout testis compared to the wild-type testis [14] .
TGFb2/TGFBR3-Mediated Effects on TGFb Superfamily Expression
Interestingly, the absence of Tgfbr3 differentially affected TGFb superfamily gene expression in freshly isolated fetal testis tissues. Notably, Tgfbr3 null testis exhibited significantly lower levels of Tgfb1 and Tgfb2 mRNA expression at 12.5 dpc, which coincides with initial cord formation in wild-type testis and the onset of testis dysgenesis in the Tgfbr3 null mutants. We observed a similar decrease in Tgfb1 and Tgfb2 mRNA levels in Tgfbr3 null fetal kidney, the effect of which may compound the effects of the gene mutation alone on TGFbmediated cellular processes [28] . In addition, while Inha, Inhba, and Inhbb are steadily upregulated in wild-type testis between 11.5-14.5 dpc, these genes are not upregulated in Tgfbr3 null testis during this period, resulting in significantly lower levels of all three genes by 14.5 dpc. This may have implications for Sertoli and Leydig cell development because compromised inhibin and activin function has been linked to the development and/or functioning of these somatic cell types during later stages of testis development [11, 29] .
Analysis of TGFb gene expression in explanted 13.5 dpc testis, cultured for 2 days, revealed differences in gene regulation between freshly isolated fetal testis from 14.5 dpc embryos. Specifically, Tgfbr3 null explants exhibited significant decreases in Tgfb1 and Tgfb2 mRNA expression relative to wild-type explants that were only observed in freshly isolated fetal testis at 12.5 dpc. Conversely, 14.5 dpc Tgfbr3 null testis exhibited significant reductions in Inha, Inhba, and Inhbb while cultured explants exhibited significant differences only in Inhba expression. The underlying causes of these differences are not currently clear, but these discrepancies may be indicative of a paracrine regulation in vivo that is not replicated in vitro and that should be taken into consideration when interpreting the data derived from testis explants.
In conclusion, the gonad explant culture method used in this study has allowed novel insights into the function of Tgfbr3 relative to TGFb2 at the molecular and cellular level during testis development. Our observations using this method combined with those in Tgfbr3 null testis support a role of the TGFb signaling pathway in testicular dysgenesis. We conclude that 1) compromised cord development and/or maintenance, but not reduced steroidogenesis, due to loss of Tgfbr3 in the differentiating fetal testis is regulated by TGFb2, 2) the reduction in steroidogenesis may be regulated by other TGFBR3 ligands, and 3) both cord and somatic cell SARRAJ ET AL. development are highly sensitive to the levels of TGFb2. Future studies should dissect the roles of TGFBR3 ligands such as the other TGFb isoforms, inhibin, and activin in TDS.
